Your browser doesn't support javascript.
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.
Miyakawa, Kei; Stanleyraj, Jeremiah Sundararaj; Kato, Hideaki; Yamaoka, Yutaro; Go, Hirofumi; Yajima, Satoshi; Shimada, Tomoko; Mihara, Takahiro; Goto, Atsushi; Yamanaka, Takeharu; Ryo, Akihide.
  • Miyakawa K; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Stanleyraj JS; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Kato H; Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan.
  • Yamaoka Y; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Go H; Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Japan.
  • Yajima S; Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Shimada T; Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan.
  • Mihara T; Nursing Department, Yokohama City University Hospital, Yokohama, Japan.
  • Goto A; Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan.
  • Yamanaka T; Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan.
  • Ryo A; Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
J Mol Cell Biol ; 2021 Aug 27.
Article in English | MEDLINE | ID: covidwho-1376314
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple VOC of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Diagnostic study / Qualitative research Language: English Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Diagnostic study / Qualitative research Language: English Year: 2021
...